Immuneering (IMRX) Stock Price, News & Analysis

Company Overview

Immuneering Corporation is a clinical-stage biotechnology company developing medicines for cancer. The company uses computational biology and drug-discovery approaches to study disease patterns and identify potential therapeutic targets, with a focus on the MAPK signaling pathway, which is involved in many cancers.

Its lead drug candidate, atebimetinib (IMM-1-104), is an oral investigational therapy designed to inhibit MEK proteins and disrupt MAPK signaling. Immuneering is evaluating this candidate for solid tumors, including pancreatic cancer, and is advancing additional drug candidates aimed at cancer-related pathways.

Founded in 2008, Immuneering is headquartered in Cambridge, Massachusetts. Co-founder Benjamin Zeskind serves as the company’s chief executive officer.

Key Stats

• Today's Range: $3.65 to $3.89
• 50-Day Range: $3.37 to $5.04
• 52-Week Range: $3.35 to $8.48
• Volume: 476,849 shs
• Average Volume: 766,947 shs
• Market Capitalization: $237.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.67
• Consensus Rating: Moderate Buy

Immuneering Stock Analysis - MarketRank™

Immuneering scored higher than 48% of companies evaluated by MarketBeat, and ranked 551st out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Immuneering has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Immuneering has a consensus price target of $15.67, representing about 326.9% upside from its current price of $3.67.

Amount of Analyst Coverage

Immuneering has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immuneering are expected to decrease in the coming year, from ($1.19) to ($1.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immuneering is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immuneering is -3.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immuneering has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.48% of the float of Immuneering has been sold short.

Short Interest Ratio / Days to Cover

Immuneering has a short interest ratio ("days to cover") of 19.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Immuneering has recently decreased by 10.59%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immuneering does not currently pay a dividend.

Dividend Growth

Immuneering does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.33

News Sentiment

Immuneering has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Immuneering this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for IMRX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Immuneering to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immuneering insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.90% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 10/29/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMRX
• CIK: 1790340
• Web: www.immuneering.com
• Phone: 617-500-8080
• Fax: N/A
• Employees: 65
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Immuneering: $15.67
• High Price Target: $20.00
• Low Price Target: $11.00
• Potential Upside/Downside: +326.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.03 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -33.91%
• Return on Assets: -32.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.97
• Quick Ratio: 13.97

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.60 per share
• Price / Book: 1.41

Miscellaneous

• Outstanding Shares: 64,760,000
• Free Float: 55,113,000
• Market Cap: $237.67 million
• Optionable: Optionable
• Beta: 0.49